A groundbreaking study on cardiac shockwave therapy, published in the esteemed European Heart Journal, has shown significant advancements in heart tissue regeneration post-coronary bypass surgery. This pivotal research was co-authored by Dr. Wolfgang Schaden, SoftWave TRT’s Medical Director and a pioneering figure in the shockwave industry.
Dr. Schaden expressed his profound impact on the developments, "I never thought I'd see the day where our technology could achieve such miraculous results, given the hurdles we've faced over the years," he shared in a BBC News medical report. He added, "Dr. Johannes Holfeld, who led this study, has performed nothing short of heroic work."
Conducted at the Medical University of Innsbruck by Dr. Holfeld, the study involved an interim analysis of 63 patients suffering from ischemic heart failure, all of whom underwent coronary bypass surgery. Post-surgery, these patients received shockwave treatments that significantly improved their left ventricular ejection fraction (LVEF) by 11.3% after one year, compared to only 6.3% in the control group receiving sham treatments. The improvements in LVEF are known to enhance survival rates and reduce hospitalizations due to heart failure. Furthermore, patients treated with shockwaves reported better quality of life and greater independence in daily activities.
Due to these significant findings, the ethics committee agreed to terminate the study early, as it was considered unethical to withhold such beneficial treatment from the control group.
John Warlick, founder of SoftWave TRT, stated, "Improving patient’s ejection fraction by 36% with a single treatment not only revolutionizes ischemic heart disease care but also sets the stage for regenerative therapies in other organs."
Over a decade ago, SoftWave TRT’s cardiology subsidiary began animal trials and treated cardiac patients with shockwave therapy, laying the groundwork for this clinical trial. “This publication is the result of over a decade of rigorous scientific research and represents a major advancement in medical science,” commented Dr. John David Mullins, a U.S.-based reconstructive surgeon and Medical Director for SoftWave TRT.
Dr. David Dean, former Director of the Samsky Advanced Heart Failure Center, praised the study, "It's the most revolutionary science I've seen in cardiac treatment. The results are simply remarkable."
John Warlick also highlighted the broader implications, "Heart disease remains the leading cause of death globally, and this trial offers hope to many who suffer daily. This technology doesn’t just prevent deterioration; it improves patients' lives significantly."
These compelling results are backed by significant investment, with over $10 million committed to the research, showcasing unprecedented outcomes in treating ischemic heart conditions.
References
European Heart Journal (2024, June 20). Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischemic heart failure: the CAST-HF trial | European Heart Journal | Oxford Academic (oup.com)
BBC News (2024, June 20). ‘Space hairdryer’ regenerates heart tissue in study (bbc.com)
About SoftWave by Molotherapy
Based in Columbia, MO, SoftWave by Molotherapy utilizes extracorporeal shockwave therapy (ESWT). Known for its German engineering excellence, SoftWave TRT is a trusted leader in the medical research community worldwide. SoftWave’s technology is proven effective across numerous studies and holds FDA clearance for multiple therapeutic applications, including chronic diabetic foot ulcer treatment, acute second-degree burn management, and pain reduction. SoftWave continues to lead the way in advancing the field of tissue regeneration and healing.
Comments